Information Provided By:
Fly News Breaks for June 18, 2019
BMRN
Jun 18, 2019 | 06:42 EDT
After hosting a call with the company's CEO Jean-Jacques Bienaime and Head of R&D Hank Fuchs, JPMorgan analyst Cory Kasimov says BioMarin remains a "high conviction long-term idea." The analyst highlights the company's orphan-focused, "diversified" base business, "growing" commercial portfolio, and "potentially disruptive" late-stage pipeline. The analyst notes that BioMarin management does not believe the company is are getting enough credit for its pipeline opportunities and that investor concerns around competitive risks are overblown. Kasimov reiterates an Overweight rating on BioMarin shares with a $133 price target.
News For BMRN From the Last 2 Days
There are no results for your query BMRN